316 related articles for article (PubMed ID: 31191873)
1. TNF-α inhibitors in the treatment of hidradenitis suppurativa.
Savage KT; Flood KS; Porter ML; Kimball AB
Ther Adv Chronic Dis; 2019; 10():2040622319851640. PubMed ID: 31191873
[TBL] [Abstract][Full Text] [Related]
2. Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.
Heidari A; Ghane Y; Heidari N; Hosseini S; Goodarzi A
Ther Adv Chronic Dis; 2024; 15():20406223241257342. PubMed ID: 38827348
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
5. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
7. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
8. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.
Ruggiero A; Martora F; Picone V; Marano L; Fabbrocini G; Marasca C
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203664
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
11. Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report.
Esme P; Akoglu G; Caliskan E
Skin Appendage Disord; 2021 Jan; 7(1):58-61. PubMed ID: 33614722
[TBL] [Abstract][Full Text] [Related]
12. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.
van Rappard DC; Limpens J; Mekkes JR
J Dermatolog Treat; 2013 Oct; 24(5):392-404. PubMed ID: 22397574
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
Haslund P; Lee RA; Jemec GB
Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
Fotiadou C; Vakirlis E; Ioannides D
Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab to treat hidradenitis suppurativa.
Shadid A; Alobaida S; Binamer Y
Dermatol Reports; 2023 Jun; 15(2):9566. PubMed ID: 37397399
[TBL] [Abstract][Full Text] [Related]
17. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A; Marinović B; Bukvić Mokos Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
Poulin Y
J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of immunomodulatory therapies for hidradenitis suppurativa.
Lim SYD; Oon HH
Biologics; 2019; 13():53-78. PubMed ID: 31190730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
